DiaMedica Therapeutics Inc. (DMAC) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US25253X2071
DiaMedica Therapeutics Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -34.40 m USD |
| EBIT | -34.41 m USD |
| Net income | -32.77 m USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
More stocks
- Qingdao Liqun Department Store Group Co Ltd (601366.SS)
- Medprin Regenerative Medical Technologies Co. Ltd. (301033.SZ)
- Xiamen Sunrise Wheel Group Co Ltd (002593.SZ)
- AUPU Home Style Corp Ltd (603551.SS)
- ADAMAS TRUST, INC. (ADAM)
- Hefei Lifeon Pharmaceutical Co Ltd (003020.SZ)
- ETHAN ALLEN INTERIORS INC (ETD)
- Neurogene Inc. (NGNE)
- Grupo Empresarial San Jose SA (GSJ.MC)
- GREENLIGHT CAPITAL RE, LTD. (GLRE)
- Beijing Scitop Bio Tech Co Ltd (300858.SZ)
- SUNSEA Telecommunications Co Ltd (002313.SZ)
Not investment advice. All data without warranty, price as of 09.11.2026. Details in the risk notice.